Lyell Immunopharma, Inc.
Quick facts
Phase 3 pipeline
- rondecabtagene autoleucel · Oncology
Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Lyell Immunopharma, Inc.
What is Lyell Immunopharma, Inc.'s pipeline?
Lyell Immunopharma, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include rondecabtagene autoleucel.
Related
- Sector hub: All tracked pharma companies